Sub head

Based on seminal research pioneered by our founders, we are targeting amyloid-beta oligomers. Overwhelming scientific evidence now indicates that these oligomers are the most toxic form of amyloid-beta, causing acute synaptic toxicity to neurons, leading to the memory and cognitive impairment and chronic neurodegeneration that are the hallmark of Alzheimer’s.

Most Alzheimer’s drugs in clinical trials address other forms of amyloid-beta without selectively targeting toxic amyloid-beta oligomers, and they have been met with challenging safety and efficacy in studies.